🚀 VC round data is live in beta, check it out!
Biohit Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biohit and similar public comparables like Nortech Systems, Mentice, Diagnostic Medical Systems, SciBase Holding and more.
Biohit Overview
About Biohit
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations.
Founded
1988
HQ
Employees
46
Website
Financials (LTM)
EV
$36M
Biohit Financials
Biohit reported last 12-month revenue of $19M and EBITDA of $4M.
In the same LTM period, Biohit generated $4M in EBITDA.
Revenue (LTM)
Biohit P&L
In the most recent fiscal year, Biohit reported revenue of $19M and EBITDA of $4M.
Biohit expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $19M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $4M | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $3M | XXX | XXX | XXX |
| Net Margin | — | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biohit Stock Performance
Biohit has current market cap of $40M, and enterprise value of $36M.
Market Cap Evolution
Biohit's stock price is $2.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36M | $40M | -1.8% | XXX | XXX | XXX | $0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiohit Valuation Multiples
Biohit trades at 1.9x EV/Revenue multiple, and 9.3x EV/EBITDA.
EV / Revenue (LTM)
Biohit Financial Valuation Multiples
As of April 14, 2026, Biohit has market cap of $40M and EV of $36M.
Equity research analysts estimate Biohit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biohit has a P/E ratio of 12.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.3x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.9x | XXX | XXX | XXX |
| P/E | — | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (22.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biohit Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biohit Margins & Growth Rates
Biohit's revenue in the last 12 month grew by 8%.
Biohit's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Biohit's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biohit's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Biohit Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (9%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biohit Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Nortech Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Mentice | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnostic Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| SciBase Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| OssDsign | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biohit M&A Activity
Biohit acquired XXX companies to date.
Last acquisition by Biohit was on XXXXXXXX, XXXXX. Biohit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biohit
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiohit Investment Activity
Biohit invested in XXX companies to date.
Biohit made its latest investment on XXXXXXXX, XXXXX. Biohit invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biohit
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biohit
| When was Biohit founded? | Biohit was founded in 1988. |
| Where is Biohit headquartered? | Biohit is headquartered in Finland. |
| How many employees does Biohit have? | As of today, Biohit has over 46 employees. |
| Is Biohit publicly listed? | Yes, Biohit is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Biohit? | Biohit trades under BIOBV ticker. |
| When did Biohit go public? | Biohit went public in 1999. |
| Who are competitors of Biohit? | Biohit main competitors are Nortech Systems, Mentice, Diagnostic Medical Systems, SciBase Holding. |
| What is the current market cap of Biohit? | Biohit's current market cap is $40M. |
| What is the current revenue of Biohit? | Biohit's last 12 months revenue is $19M. |
| What is the current revenue growth of Biohit? | Biohit revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Biohit? | Current revenue multiple of Biohit is 1.9x. |
| Is Biohit profitable? | Yes, Biohit is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biohit? | Biohit's last 12 months EBITDA is $4M. |
| What is Biohit's EBITDA margin? | Biohit's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Biohit? | Current EBITDA multiple of Biohit is 9.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.